Respiratory Molecular Diagnostics Market: By Technology (Polymer Chain Reaction And Next-Generation Sequencing), By Disease Indication (Viruses, Bacteria, And Others), By End-users (Hospital, Research Institution, Point Of Care Setting, And Diagnostic Laboratories) and Geography

Respiratory Molecular Diagnostics Market is expected to grow at a compound annual growth rate (CAGR) of 7.1%. The rising prevalence of respiratory illnesses, particularly among the aging population, increased demand for advanced diagnostics with the integration of AI, data analysis, and technological advancements (imaging, molecular diagnostics, rapid tests) are fuelling the respiratory molecular diagnostics market. This growth is driven by the need for early detection, personalized treatment, and efficient response to outbreaks. Conversely, environmental pollution increases the patient pool, while the COVID-19 pandemic significantly boosted the market due to the need for accurate and rapid testing. Hospitals adopted stricter protocols to prevent cross-infection during the pandemic, leading to increased focus on respiratory diagnostics. However, the high cost of advanced technologies for diagnostics and the limited resources and awareness remain challenges and hurdles.

Respiratory Molecular Diagnostics Market Key Developments:

• In 2023, The Alinity m Resp-4-Plex assay, a one-step test approved by the FDA, detects and differentiates between SARS-CoV-2, influenza A/B, and respiratory syncytial virus.
• August 2, 2023, Becton, Dickinson and Company (BD) has received 510(k) clearance from the US Food and Drug Administration (FDA) for its single molecular diagnostic combination test, BD Respiratory Viral Panel (RVP) for BD MAX System.